NPM1 and acute myeloid leukemia: The KOMET-007 phase I clinical study evaluated the safety and the efficacy of Ziftomenib combined with standard chemotherapy in 34 newly diagnosed AML patients with KMT2A rearrangements or NPM1 mutations; the patients were treated either with 200 or 400 mg of Ziftomenib [124].